- Home
- AGEN
AGEN
Agenus Inc.
as 07-26-2024 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 125.8M | IPO Year: | 2000 |
| Target Price: | $37.33 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.78 - $32.00 | Next Earning Date: | 08-08-2024 |
| Revenue: | $161,416,000 | Revenue Growth: | 69.94% |
| Revenue Growth (this year): | 43.78% | Revenue Growth (next year): | -12.93% |
Stock Insider Trading Activity of Agenus Inc. (AGEN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ARMEN GARO H | AGEN | See Remarks | Feb 15 '24 | Buy | $0.65 | 500,000 | $324,050.00 | 625,969 | SEC Form 4 |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Business Wire
13 hours ago
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
Zacks
7 days ago
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
BioPharma Dive
8 days ago
Lilly alone in bidding for Morphic; Novartis won’t yet file MorphoSys drug
MT Newswires
8 days ago
Agenus Says FDA Advised Against Accelerated Approval for Potential Colorectal Cancer Treatment; Shares Tumble
Business Wire
9 days ago
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
Zacks
14 days ago
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
MT Newswires
a month ago
Sector Update: Health Care Stocks Edge Higher in Afternoon Trading
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.